Kelsey Natsuhara, MD

Title(s)Clinical Fellow, Medicine
SchoolSchool of Medicine
ORCID ORCID Icon0000-0002-7352-7028 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard College, Cambridge, MABA05/2013Human Developmental and Regenerative Biology
    Harvard Medical School, Boston, MAMD05/2018
    University of California, San Francisco, CA10/2020Diversity, Equity, and Inclusion Champion Training

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma. Leuk Lymphoma. 2023 Apr 25; 1-8. Natsuhara KH, Huang CY, Knoche J, Arora S, Chung A, Martin T, Wolf J, Wong SW, Shah N, Banerjee R. PMID: 37096638.
      View in: PubMed   Mentions:    Fields:    
    2. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis. Curr Probl Cancer. 2023 Feb 14; 47(3):100953. Kennedy VE, Natsuhara K, Shah ND, Arora S, Wolf J, Martin TG, Aras MA, Chung A, Wong SW. PMID: 36807996.
      View in: PubMed   Mentions:    Fields:    
    3. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2022 04 12; 6(7):2045-2054. Kambhampati S, Sheng Y, Huang CY, Bylsma S, Lo M, Kennedy V, Natsuhara K, Martin T, Wolf J, Shah N, Wong SW. PMID: 34543400; PMCID: PMC9006279.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    4. The Distance Between Us: the COVID-19 Pandemic's Effects on Burnout Among Resident Physicians. Med Sci Educ. 2021 Dec; 31(6):2065-2069. Natsuhara KH, Borno HT. PMID: 34692226; PMCID: PMC8519327.
      View in: PubMed   Mentions: 1  
    5. Evaluating predictors of renal injury with sorafenib in hepatocellular carcinoma: A multi-ethnic cohort study. Journal of Onco-Nephrology. 2021 Apr 19; 239936932110092. Natsuhara NK, Zhang ZL, Carlos CC, Borno BH. .
      View in: Publisher Site   Mentions:
    6. Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy. Blood. 2020 Nov 5; 136(Supplement 1):4-5. Kambhampati KS, Fakhri FB, Sheng SY, Huang HC, Byslma BS, Natsuhara NK, Biswas BD, Lo LM, Ai AW, Kaplan KL, Martin MT, Wolf WJ, Shah SN, Andreadis AC, Wong WS. .
      View in: Publisher Site   Mentions:
    7. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol. 2019 Oct; 26(11):3502-3509. Wong SM, Almana N, Choi J, Hu J, Gagnon H, Natsuhara K, Shen AH, DeSantis S, Dominici L, Golshan M, Weiss A, Bellon J, Mittendorf EA, King TA. PMID: 31228134.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    8. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria. Oncologist. 2019 05; 24(5):595-602. Natsuhara KH, Losk K, King TA, Lin NU, Camuso K, Golshan M, Pochebit S, Brock JE, Bunnell CA, Freedman RA. PMID: 30076279; PMCID: PMC6516114.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    9. Nurse-midwives' ability to diagnose acute third- and fourth-degree obstetric lacerations in western Kenya. BMC Pregnancy Childbirth. 2017 Sep 18; 17(1):308. Pinder LF, Natsuhara KH, Burke TF, Lozo S, Oguttu M, Miller L, Nelson BD, Eckardt MJ. PMID: 28923011; PMCID: PMC5604156.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco type DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation. J Oncol Pract. 2017 09; 13(9):e815-e820. Losk K, Freedman RA, Lin NU, Golshan M, Pochebit SM, Lester SC, Natsuhara K, Camuso K, King TA, Bunnell CA. PMID: 28858535.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    11. Distinct Roles for Matrix Metalloproteinases 2 and 9 in Embryonic Hematopoietic Stem Cell Emergence, Migration, and Niche Colonization. Stem Cell Reports. 2017 05 09; 8(5):1226-1241. Theodore LN, Hagedorn EJ, Cortes M, Natsuhara K, Liu SY, Perlin JR, Yang S, Daily ML, Zon LI, North TE. PMID: 28416284; PMCID: PMC5425629.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    12. Implementation of surgeon-initiated Oncotype DX ordering among patients with breast cancer to reduce chemotherapy wait times. Journal of Clinical Oncology. 2017 Mar 10; 35(8_suppl):166-166. Losk LK, Freedman FR, Lin LN, Golshan GM, Lester LS, Pochebit PS, Natsuhara NK, Camuso CK, King KT, Bunnell BC. .
      View in: Publisher Site   Mentions:
    13. Distinct roles for matrix metalloproteinases 2 and 9 in embryonic hematopoietic stem cell production. Experimental Hematology. 2016 Sep 1; 44(9):s103. Theodore TL, Cortes CM, Natsuhara NK, Liu LS, Esain EV, North NT. .
      View in: Publisher Site   Mentions:
    14. Transforming the clinical trial process: The I-SPY 2 trial as a model for improving the efficiency of clinical trials and accelerating the drug-screening process. Journal of Clinical Oncology. 2014 May 20; 32(15_suppl):tps2633-tps2633. Buxton BM, Natsuhara NK, DeMichele DA, Perlmutter PJ, Hylton HN, Yee YD, van't Veer vL, Symmans SW, Hogarth HM, Lyandres LJ, Davis DS, Flynn FS, Paoloni PM, Berry BD, Esserman EL. .
      View in: Publisher Site   Mentions:
    Kelsey's Networks
    Concepts (64)
    Derived automatically from this person's publications.
    Co-Authors (11)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department